Ozagrel Sodium | KCT-0809 | Cataclot | CAS#189224-26-8 | CAS#82571-53-7 | Thromboxane A2 Synthesis Inhibitor

MedKoo Cat#: 328502 | Name: Ozagrel Sodium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ozagrel Sodium, also known as KCT-0809 and Cataclot, is a anti-vasospasm agent and a thromboxane A2 synthase inhibitor used to treat cerebrovascular diseases.

Chemical Structure

Ozagrel Sodium

CAS#189224-26-8 (sodium)

Theoretical Analysis

MedKoo Cat#: 328502

Name: Ozagrel Sodium

CAS#: 189224-26-8 (sodium)

Chemical Formula: C13H11N2NaO2

Exact Mass: 0.0000

Molecular Weight: 250.23

Elemental Analysis: C, 62.40; H, 4.43; N, 11.20; Na, 9.19; O, 12.79

Price and Availability

Size	Price	Availability	Quantity
500mg	USD 550.00
1g	USD 950.00
2g	USD 1,650.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

189224-26-8 (sodium) 82571-53-7 (free base) 74003-18-2 (HCl)

Synonym

Ozagrel Sodium; KCT-0809; KCT 0809; KCT0809; Cataclot; Xanbo

IUPAC/Chemical Name

sodium (E)-3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylate

InChi Key

NCNYJCOBUTXCBR-IPZCTEOASA-M

InChi Code

InChI=1S/C13H12N2O2.Na/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;/h1-8,10H,9H2,(H,16,17);/q;+1/p-1/b6-5+;

SMILES Code

O=C([O-])/C=C/C1=CC=C(CN2C=CN=C2)C=C1.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 82571-53-7 (Ozagrel) 189224-26-8 (Ozagrel Sodium)

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor.

In vitro activity:

Pretreatment of blood with ozagrel, an inhibitor of TxAS, also inhibited 12-HHT and TxB2 production in a dose-dependent manner. Treatment of human platelets with 10 µM ozagrel almost completely inhibited thrombin-induced TxB2 production, and 12-HHT production was inhibited by 40–60% (Fig. 2B, supplementary Fig. III-B). Conversely, production of PGD2 and PGE2 was markedly increased by ozagrel treatment. Reference: J Lipid Res. 2013 Nov;54(11):2979-87. https://pubmed.ncbi.nlm.nih.gov/24009185/

In vivo activity:

This study examined the effect of ozagrel, a thromboxane A(2) synthase inhibitor, on the accumulation of leucocytes and chemokine mRNA expression in lungs experimentally injured using oleic acid (OA). OA injection into guinea pigs rapidly increased thromboxane A(2) generation and subsequently increased total protein concentration and the numbers of macrophages and neutrophils in bronchoalveolar lavage fluid and increased monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in the whole lung. Administration of ozagrel prevented these changes associated with OA injection. Reference: J Pharmacol Sci. 2009 Oct;111(2):211-5. https://pubmed.ncbi.nlm.nih.gov/19783866/

	Solvent	mg/mL	mM
Solubility
	DMSO	3.6	14.49
	Water	50.0	199.81

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 250.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Matsunobu T, Okuno T, Yokoyama C, Yokomizo T. Thromboxane A synthase-independent production of 12-hydroxyheptadecatrienoic acid, a BLT2 ligand. J Lipid Res. 2013 Nov;54(11):2979-87. doi: 10.1194/jlr.M037754. Epub 2013 Sep 5. PMID: 24009185; PMCID: PMC3793602. 2. Ishitsuka Y, Moriuchi H, Isohama Y, Tokunaga H, Hatamoto K, Kurita S, Irikura M, Iyama K, Irie T. A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci. 2009 Oct;111(2):211-5. doi: 10.1254/jphs.09128sc. Epub 2009 Sep 26. PMID: 19783866. 3. Imamura T, Kiguchi S, Kobayashi K, Ichikawa K, Yamazaki Y, Kojima M. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. Arzneimittelforschung. 2003;53(10):688-94. doi: 10.1055/s-0031-1299813. PMID: 14650360.

In vitro protocol:

In vivo protocol:

1. Ishitsuka Y, Moriuchi H, Isohama Y, Tokunaga H, Hatamoto K, Kurita S, Irikura M, Iyama K, Irie T. A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci. 2009 Oct;111(2):211-5. doi: 10.1254/jphs.09128sc. Epub 2009 Sep 26. PMID: 19783866. 2. Imamura T, Kiguchi S, Kobayashi K, Ichikawa K, Yamazaki Y, Kojima M. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. Arzneimittelforschung. 2003;53(10):688-94. doi: 10.1055/s-0031-1299813. PMID: 14650360.

1: Magara H, Tani T, Imai S, Kiyomi A, Fushimi K, Sugiura M. Fasudil hydrochloride and ozagrel sodium combination therapy for patients with aneurysmal subarachnoid hemorrhage: a cross-sectional study using a nationwide inpatient database. J Pharm Health Care Sci. 2024 Aug 13;10(1):49. doi: 10.1186/s40780-024-00370-w. PMID: 39138543. 2: Shahali H, Farahani RH, Asgari A, Hazrati E. Thalamic hemi-chorea: a rare complication after receiving the adenoviral vector-based COVID-19 vaccine: a case report. Clin Exp Vaccine Res. 2022 May;11(2):217-221. doi: 10.7774/cevr.2022.11.2.217. Epub 2022 May 31. PMID: 35799877; PMCID: PMC9200646. 3: Yu Y, Wang L, Zhu X, Liu YF, Ma HY. Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction. World J Diabetes. 2021 Dec 15;12(12):2096-2106. doi: 10.4239/wjd.v12.i12.2096. PMID: 35047123; PMCID: PMC8696649. 4: Miyayama S, Yamashiro M, Ikeda R, Matsumoto J, Ogawa N, Sakuragawa N, Ueda T. Cerebral Embolism as a Rare Complication of Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices: A Case Report. Interv Radiol (Higashimatsuyama). 2021 Feb 28;6(1):9-13. doi: 10.22575/interventionalradiology.2020-0024. PMID: 35910526; PMCID: PMC9327304. 5: Ido K, Kurogi R, Kurogi A, Nishimura K, Arimura K, Nishimura A, Ren N, Kada A, Matsuo R, Onozuka D, Hagihara A, Takagishi S, Yamagami K, Takegami M, Nohara Y, Nakashima N, Kamouchi M, Date I, Kitazono T, Iihara K; J-ASPECT Study Collaborators. Effect of treatment modality and cerebral vasospasm agent on patient outcomes after aneurysmal subarachnoid hemorrhage in the elderly aged 75 years and older. PLoS One. 2020 Apr 9;15(4):e0230953. doi: 10.1371/journal.pone.0230953. PMID: 32271814; PMCID: PMC7145106. 6: Narayan V, Shukla D, Bhat DI, Prabhuraj AR, Devi BI. Ozagrel for Postoperative Management of Aneurysmal Subarachnoid Hemorrhages. Neurol India. 2019 Sep-Oct;67(5):1286-1289. doi: 10.4103/0028-3886.271236. PMID: 31744960. 7: Nishimura A, Nishimura K, Onozuka D, Matsuo R, Kada A, Kamitani S, Higashi T, Ogasawara K, Shimodozono M, Harada M, Hashimoto Y, Hirano T, Hoshino H, Itabashi R, Itoh Y, Iwama T, Kohriyama T, Matsumaru Y, Osato T, Sasaki M, Shiokawa Y, Shimizu H, Takekawa H, Nishi T, Uno M, Yagita Y, Ido K, Kurogi A, Kurogi R, Arimura K, Ren N, Hagihara A, Takizawa S, Arai H, Kitazono T, Miyamoto S, Minematsu K, Iihara K; J-ASPECT study collaborators. Development of Quality Indicators of Stroke Centers and Feasibility of Their Measurement Using a Nationwide Insurance Claims Database in Japan　― J-ASPECT Study ―. Circ J. 2019 Oct 25;83(11):2292-2302. doi: 10.1253/circj.CJ-19-0089. Epub 2019 Sep 26. PMID: 31554766. 8: Jin L, Zhou J, Shi W, Xu L, Sheng J, Fan J, Yuan Y, Yuan H. Effects of six types of aspirin combination medications for treatment of acute cerebral infarction in China: A network meta-analysis. J Clin Pharm Ther. 2019 Feb;44(1):91-101. doi: 10.1111/jcpt.12763. Epub 2018 Sep 17. PMID: 30225937. 9: Zhou P, Du S, Zhou L, Sun Z, Zhuo LH, He G, Zhao Y, Wu Y, Zhang X. Tetramethylpyrazine‑2'O‑sodium ferulate provides neuroprotection against neuroinflammation and brain injury in MCAO/R rats by suppressing TLR-4/NF-κB signaling pathway. Pharmacol Biochem Behav. 2019 Jan;176:33-42. doi: 10.1016/j.pbb.2018.08.010. Epub 2018 Aug 29. PMID: 30171935. 10: Andoh T, Li S, Uta D. Involvement of thromboxane A2 in interleukin-31-induced itch-associated response in mice. Pharmacol Rep. 2018 Apr;70(2):251-257. doi: 10.1016/j.pharep.2017.10.001. Epub 2017 Oct 5. PMID: 29477033. 11: Himeno T, Takeshima S, Kubo S, Hara N, Tanaka A, Kuriyama M. [Trigeminal Herpes Zoster Presenting with High-intensity Signals for the Spinal Trigeminal Nucleus and Tract on Diffusion-weighted Image: A Case Report of Stroke Mimic]. Brain Nerve. 2018 Feb;70(2):161-164. Japanese. doi: 10.11477/mf.1416200969. PMID: 29433118. 12: Jiang JJ, Xie YM, Zhang Y, Zhang YK, Wang ZM, Han B. [Clinical medication characteristics of Shuxuening injection in treatment of cerebral infarction research based on registration]. Zhongguo Zhong Yao Za Zhi. 2016 Dec;41(24):4516-4520. Chinese. doi: 10.4268/cjcmm20162407. PMID: 28936832. 13: Yoshida J, Kubo Y, Yoshida K, Chida K, Kobayashi M, Ogasawara K. [Development of Intracerebral Hemorrhage and Subarachnoid Hemorrhage Shortly after Cerebral Infarction Onset in an Adult Patient with Moyamoya Disease]. No Shinkei Geka. 2017 Feb;45(2):139-146. Japanese. doi: 10.11477/mf.1436203465. PMID: 28202831. 14: Wada T, Yasunaga H, Horiguchi H, Fushimi K, Matsubara T, Nakajima S, Yahagi N. Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis. J Stroke Cerebrovasc Dis. 2016 Dec;25(12):2828-2837. doi: 10.1016/j.jstrokecerebrovasdis.2016.07.044. Epub 2016 Aug 25. PMID: 27567296. 15: Xu SH, Yin MS, Liu B, Chen ML, He GW, Zhou PP, Cui YJ, Yang D, Wu YL. Tetramethylpyrazine-2'-O-sodium ferulate attenuates blood-brain barrier disruption and brain oedema after cerebral ischemia/reperfusion. Hum Exp Toxicol. 2017 Jul;36(7):670-680. doi: 10.1177/0960327116657401. Epub 2016 Jul 6. PMID: 27387348. 16: Andoh T, Yamamoto A, Haza S, Yuhki KI, Ushikubi F, Narumiya S, Kuraishi Y. Thromboxane A2 is Involved in Itch-associated Responses in Mice with Atopic Dermatitis-like Skin Lesions. Acta Derm Venereol. 2016 Nov 2;96(7):899-904. doi: 10.2340/00015555-2437. PMID: 27066774. 17: Park SI, Park SK, Jang KS, Han YM, Kim CH, Oh SJ. Preischemic neuroprotective effect of minocycline and sodium ozagrel on transient cerebral ischemic rat model. Brain Res. 2015 Mar 2;1599:85-92. doi: 10.1016/j.brainres.2014.12.051. Epub 2014 Dec 31. PMID: 25555371. 18: Tanahashi N. [Antiplatelet therapy for secondary prevention of cerebral infarction]. Nihon Rinsho. 2014 Jul;72(7):1270-5. Japanese. PMID: 25163320. 19: Yang B, Shi J, Chen X, Ma B, Sun H. Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials. PLoS One. 2014 Feb 13;9(2):e88440. doi: 10.1371/journal.pone.0088440. PMID: 24551100; PMCID: PMC3923787. 20: Ishibashi A, Yoshitake Y, Adachi H. Investigation of effect of edaravone on ischemic stroke. Kurume Med J. 2013;60(2):53-7. doi: 10.2739/kurumemedj.ms62009. Epub 2013 Dec 2. PMID: 24291782.